The emergence of T-Bodies/CAR T cells

Cancer Journal (United States)

Volumn 20, Issue 2, 2014, Pages 123-126

  Eshhar, Zelig ^a   Waks, Tova ^a,b   Gross, Gideon ^c,d  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^d TEL HAI COLLEGE   (Israel)

Author keywords

cancer immunotherapy; CAR; cell and gene engineering; Chimeric receptors; T bodies

Indexed keywords

CD3 ANTIGEN; CHIMERIC ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOTOXICITY; GENE TRANSFER; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM;

ANTIGENS, CD3; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84897546972     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000027     Document Type: Review

References (53)

1. Gross G,Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024-10028.
2. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
3. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6056.
4. Kochenderfer JN,Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099-4102.
5. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.
6. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
7. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.
8. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
9. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5177ra38.
10. Ochi A, Hawley RG, Hawley T, et al. Functional immunoglobulinMproduction after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells. Proc Natl Acad Sci U S A. 1983;80:6351-6355.
11. Goverman J, Gomez SM, Segesman KD, et al. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. Cell. 1990;60:929-939.
12. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720-724.
13. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85:5879-5883.
14. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigenbinding proteins. Science (United States). 1988;242:423-426.
15. Moritz D, Groner B. A spacer region between the single chain antibodyand the CDS ζ-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 1995;2:539-546.
16. Mezzanzanica D, Canevari S, Mazzoni A, et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 1998;5:401-407.
17. Fitzer-Attas CJ, Schindler DG, Waks T, et al. Harnessing syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol. 1998;160:145-154.
18. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28:203-211.
19. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206-1213.
20. Combadière B, Freedman M, Chen L, et al. Qualitative and quantitative contributions of the T cell receptor ζ chain to mature T cell apoptosis. J Exp Med. 1996;183:2109-2117.
21. ZhaoY,Wang QJ,Yang S, et al.Aherceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183:5563-5574.
22. Gerstmayer B, Altenschmidt U, Hoffmann M, et al. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. J Immunol. 1997;158:4584-4590.
23. Finney HM, Lawson ADG, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161:2791-2797.
24. Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28- OX40 "super-stimulation". Mol Ther. 2013;21:2268-2277.
25. Vonderheide RH, June CH. Engineering T cells for cancer: our synthetic future. Immunol Rev. 2014;257:7-13.
26. Chang L, Chang WC, McNamara G, et al. Transgene-enforced costimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. Cytotherapy (England). 2007;9:771-784.
27. Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/ AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (United States). 2010;18:413-420.
28. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71:4617-4627.
29. Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood t cells against b-cell malignancies. Hum Gene Ther. 2010;21:75-86.
30. Bach NL, Waks T, Schindler DG, et al. Functional expression in mast cells of chimeric receptors with antibody specificity. Cell Biophys (United States). 1994;24-25:229-236.
31. Bach N,Waks T, Eshhar Z. Specific lysis of tumor cells by an NK-like cell line transfected with chimeric receptor genes. Tumor Targeting. 1995;1:203.
32. Eshhar Z, Gross G. Chimeric T cell receptor which incorporates the anti-tumour specificity of a monoclonal antibody with the cytolytic activity of T cells: a model system for immunotherapeutical approach. Br J Cancer Suppl. 1990;10:27-29.
33. Gross G, Levy S, Levy R, et al. Chimaeric T-cell receptors specific to a B-lymphoma idiotype: a model for tumour immunotherapy. Biochem Soc Trans. 1995;23:1079-1082.
34. Stancovski I, Schindler DG, Waks T, et al. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain fv receptors. J Immunol. 1993;151:6577-6582.
35. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the fc receptor gamma chain. J Exp Med (United States). 1993;178:361-366.
36. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
37. Daly T, Royal RE, Kershaw MH, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther (ENGLAND). 2000;7:284-291.
38. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-6115.
39. Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A. 1994;91:4318-4322.
40. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233-240.
41. Pinthus JH, Waks T, Kaufman-Francis K, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res. 2003;63:2470-2476.
42. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114:1774-1781.
43. Maliar A, Servais C, Waks T, et al. Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology. 2012;143:1375-1384.e5.
44. Friedmann-Morvinski D, Bendavid A, Waks T, et al. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 2005;105:3087-3093.
45. Friedmann-Morvinski D,Waks T, Marcus A, et al. Adoptive cell therapy of systemic metastases using erbB-2-specific T cells redirected with a chimeric antibody-based receptor. Curr Cancer Res. 2014;12:107-122.
46. Marcus A, Waks T, Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood. 2011;118:975-983.
47. Marcus A, Eshhar Z. Tumor-specific allogeneic cells for cancer therapy. Exp Opin Biol Ther. 2011;11:1551-1554.
48. Gschweng E, De Oliveira S, Kohn DB. Hematopoietic stem cells for cancer immunotherapy. Immunol Rev. 2014;257:237-249.
49. Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928-933.
50. Torikai H, Reik A, Liu P-, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimericantigen- receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697-5705.
51. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant:Aphase I study. Blood. 2013;122:2965-2973.
52. Lamers CHJ, Sleijfer S, Van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21:904-912.
53. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with achimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-851.